Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 7, Issue -, Pages D1609-D1623Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/angio
Keywords
endothelial growth factors; angiogenesis factor; vascular endothelial growth factor; lung growth and development; animal disease models; bronchopulmonary dysplasia; hyperoxia; review
Categories
Funding
- NHLBI NIH HHS [K08 HL-03493] Funding Source: Medline
Ask authors/readers for more resources
Normal pulmonary vascular development is the result of a complex interplay of growth factors, including vascular endothelial growth factor (VEGF) and the angiopoietins. Injury to the developing lung, whether due to hyperoxia or mechanical ventilation, results in disordered vascular development, ranging from an apparent arrest of microvascular development in milder injury to extensive microvascular derangement in more severe injury. Alterations in vascular growth factors may participate in these injuries. During injury to the developing animal lung, VEGF abundance is markedly decreased. In models of post-injury recovery, up-regulation of VEGF accompanies the re-establishment of normal vasculature. Alterations in lung VEGF levels in human premature infants are less clear cut. However, among humans premature newborns who later go on to develop bronchopulmonary dysplasia (BPD), VEGF production is decreased in comparison to those newborns who recover. Other angiogenic factors, such as the CXC ELR+ chemokines, are also altered in injury to the developing lung, but their specific roles in vascular injury are less clear. Strategies that enhance microvascular integrity, whether through attenuating alterations in vascular growth factors or by other means, also improve the outcome of lung injury. Such therapies may eventually offer hope in human BPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available